University of California, San Francisco

Spectral Medical Provides Tigris Trial Update

Retrieved on: 
Tuesday, November 7, 2023
UCSF, NYSE, Septic shock, UAB, Emory Healthcare, Mortality, University of California, San Francisco, Hospital, University, University of Alabama, Sepsis, Patient, Randomized controlled trial, Lipopolysaccharide, TSX, Pharmaceutical industry, Nursing

TORONTO, Nov. 07, 2023 (GLOBE NEWSWIRE) --  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has enrolled a total of 76 patients for the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Key Points: 
  • TORONTO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has enrolled a total of 76 patients for the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.
  • Emory Healthcare newest trial site addition (Tigris site #20) enrolling out of two hospitals.
  • University of California San Francisco (UCSF) and University of Alabama at Birmingham (UAB) continue to be strong Tigris enrollers, with the enrollment of patients 75 and 76 at the end of October.
  • Dr. John Kellum, Chief Medical Officer of Spectral, commented, “After a somewhat sluggish September, we are pleased with October’s robust screening activity which resulted in two new enrollments at the end of October.

AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer

Retrieved on: 
Tuesday, November 7, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Alpha particle, Prostate, Prostate cancer, MD, University of California, San Francisco, University, Peter MacCallum Cancer Centre, University of California, Los Angeles, Cancer, Targeted alpha-particle therapy, PSMA, Patient, Letter, Medical imaging, Pharmaceutical industry

“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, and our patients,” said Andrew Adamovich, CEO of AdvanCell.

Key Points: 
  • “The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, and our patients,” said Andrew Adamovich, CEO of AdvanCell.
  • “We believe that 212Pb is the ideal radioisotope to realise the full therapeutic power of Targeted Alpha Therapy.
  • “We are excited to be moving this 212Pb-based therapy forward in the TheraPb clinical study.”
    Developed the world’s first 212Pb-based Targeted Alpha Therapy to enter clinical trials in metastatic prostate cancer.
  • Developed a proprietary target discovery and ligand development program encompassing a robust pipeline of Targeted Alpha Therapies to treat cancer.

Patient Experience Journal, published in association with The Beryl Institute, Releases Volume 10, Issue 3

Retrieved on: 
Tuesday, November 7, 2023
Research Institute of Healthcare Organization and Medical Management of Moscow Department of Healthcare, Medical University of Vienna, Oregon Health & Science University, Ariel University, Research, Agility, University of California, San Francisco, University, Implementation research, Medical school, University of Alabama, Northwestern Health Sciences University, University of Michigan, Movement, Nursing, Management

NASHVILLE, Tenn., Nov. 7, 2023 /PRNewswire-PRWeb/ -- The Beryl Institute announces the publication of Volume 10, Issue 3 of Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused on research and proven practices related to understanding and improving the patient experience. Read in over 220 countries and territories, PXJ articles have been downloaded over 1,100,000 times and reflect the journal's commitment to disseminating rigorous knowledge and expanding the global conversation on evidence and innovation in patient and human experience.

Key Points: 
  • "This issue closes the first decade of Patient Experience Journal's (PXJ) contribution to evidence and innovation, to sharing stories and research, to elevating the conversation and pushing the boundaries of the experience movement."
  • said Jason Wolf, Founding Editor of PXJ and President & CEO of The Beryl Institute.
  • "We have never hesitated to nudge at the status quo or to respond with agility to the challenging moments we have faced.
  • We have welcomed diverse voices as contributors, and we have seen an even more diverse readership."

Discover the latest advancements from ZEISS Microscopy at SfN Neuroscience 2023

Retrieved on: 
Friday, November 3, 2023
UNC, New York Institute of Technology, Biomedical sciences, System, Pathology, ZEISS, Medical laboratory, Neuraxial blockade, Assistant, Carl Zeiss AG, Associate professor, Research, University of California, San Francisco, University of North Carolina at Chapel Hill, University of British Columbia, Workflow, University, Brain, San Francisco, XRM, Microscopy, Max Planck Florida Institute for Neuroscience, Traumatic brain injury, Postdoctoral researcher, MS, Telescopic sight, Microscope, Neuroscience

WHITE PLAINS, N.Y., Nov. 3, 2023 /PRNewswire/ -- ZEISS Microscopy is highlighting two of their newest products at SfN Neuroscience 2023, in Washington, D.C., from November 12 to November 15, 2023. One delivers a new functionality to ZEISS laser scanning microscopes and the other is a new integrated system for serial block-face imaging.

Key Points: 
  • WHITE PLAINS, N.Y., Nov. 3, 2023 /PRNewswire/ -- ZEISS Microscopy is highlighting two of their newest products at SfN Neuroscience 2023, in Washington, D.C., from November 12 to November 15, 2023.
  • One delivers a new functionality to ZEISS laser scanning microscopes and the other is a new integrated system for serial block-face imaging.
  • ZEISS invites you to Discover the Power of Possibilities at SfN Neuroscience, booth #1323.
  • To learn more about ZEISS and SfN Neuroscience 2023, please visit: https://www.zeiss.com/microscopy/us/l/events/trade-shows/sfn-neuroscienc...

Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation

Retrieved on: 
Thursday, November 2, 2023
Multiple myeloma, CAR, Icahn Genomics Institute, Black, Associate, Washington University in St. Louis, Therapy, CRISPR, Genetics, Bone marrow, Icahn School of Medicine at Mount Sinai, Early Prostate Cancer (clinical programme), Translational research, Doctor of Philosophy, Multiple Myeloma Research Foundation, Research, MAC, Stanford University Medical Center, Mount Sinai Health System, University of California, San Francisco, Genomics, Growth, Disease, MMRF, Immunotherapy, University, Gene, Hackensack University Medical Center, San Francisco, Cancer, Patient, Marc, Pharmaceutical industry, Vaccine, MD

NEW YORK, Nov. 2, 2023 /PRNewswire-PRWeb/ -- The Mount Sinai Health System has received a $7 million grant from the Multiple Myeloma Research Foundation for a three-year project that aims to fast-track novel translational concepts to improve outcomes for people with high risk myeloma, the second most common blood cancer in the United States.

Key Points: 
  • Multiple myeloma is a blood cancer that develops in the bone marrow and can spread throughout the body.
  • In 2023, more than 35,000 Americans are projected to be diagnosed with multiple myeloma and approximately 12,000 will lose their lives.
  • Researchers hope to uncover the full landscape of genomic, proteomic and immune differences between high- and standard-risk multiple myeloma patients.
  • "The three exciting programs we selected each have potential to answer fundamental questions about multiple myeloma and help advance rational treatments for this cancer."

PolyBio Research Foundation receives $15M for extended Long COVID research and clinical trials

Retrieved on: 
Wednesday, November 1, 2023
Principal, J. Craig Venter Institute, Laboratory, Cohen Center for Holocaust and Genocide Studies, Core, Harvard Medical School, Coronavirus, UCSF, Karolinska Institute, Johns Hopkins University, Assistant, SARS-CoV-2, Nature Immunology, Physician, Icahn School of Medicine at Mount Sinai, Atmosphere, Research, Virus, University of Pennsylvania, Multimedia, University of California, San Francisco, Aerosol, COVID, Vitalik Buterin, Consortium, Clinical trial, COVID-19, Mount Sinai, N95, University, HEPA, San Francisco, Alzheimer's disease, Patient, Infection, Pharmaceutical industry, Vaccine, Long COVID, Ethereum, Medicine

MEDFORD, Mass., Nov. 1, 2023 /PRNewswire/ -- PolyBio Research Foundation has announced a $15M gift from Kanro: a philanthropic fund to support scientific research established by Vitalik Buterin, co-founder of Ethereum. The funding will support a second phase of research and clinical trials via the LongCovid Research Consortium (LCRC): a global scientific collaboration to rapidly and openly study core biological drivers of Long COVID. This is Buterin's second $15M gift to the Consortium and will allow dozens of new projects to move forward.

Key Points: 
  • The funding will support a second phase of research and clinical trials via the LongCovid Research Consortium (LCRC): a global scientific collaboration to rapidly and openly study core biological drivers of Long COVID.
  • LCRC research thus far demonstrates that reservoirs of the virus can persist for months - or even years - in the tissue of Long COVID patients.
  • "Mechanisms underlying Long COVID are not a mystery," says Dr. Amy Proal PhD, PolyBio's Chief Scientific Officer.
  • "The persistence of SARS-CoV-2 in tissue is a major target for rapid research and clinical trials."

Bay Area Lyme Foundation Now Accepting Applications for 2024 Emerging Leader Award and Grant

Retrieved on: 
Thursday, October 26, 2023
ISCB Senior Scientist Award, Lyme disease, Associate, Principal investigator, Therapy, University of California, San Francisco, MD, Doctor of Philosophy, ELA, Research, Emerging, Private sector, Bangladesh Technical Education Board, Stanford University, Brandeis University, University, Massachusetts Institute of Technology, NIH, San Francisco, Pacific Time Zone, Virginia Tech, ECLS, Hospital, Harvard University, Louisiana State University, Boston Children's Hospital, Infection, Letter, Pharmaceutical industry

This year, the Foundation ELA will present a $150,000 award for a researcher who is at the post-doctoral level through associate professor level.

Key Points: 
  • This year, the Foundation ELA will present a $150,000 award for a researcher who is at the post-doctoral level through associate professor level.
  • Even today, it presents a significant hurdle for the scientific research community,” said Wendy Adams, research grant director Bay Area Lyme Foundation.
  • Bay Area Lyme Foundation encourages researchers to explore novel, scientifically well-founded concepts with potential utility toward that goal.
  • Many ELA recipients have subsequently received grants from other groups including the NIH, as well as continued support from Bay Area Lyme Foundation.

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Retrieved on: 
Tuesday, October 24, 2023
Low back pain, Health policy, National Science Foundation: Under the Microscope, Policy, CDMI, PD, Biomarker, Society for Medical Decision Making, Lumbar disc disease, Physician, E pluribus unum, Doctor of Philosophy, Department of Medicine – University of Pamplona, Pain, Research, Society, Meta-analysis, University of California, San Francisco, Monte Carlo, ASPN, Comparison, University, ACON, ICER, Algorithm, CO, International Society, Patient, DCLP, NSF, National Science Foundation, Nursing

The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023.

Key Points: 
  • The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023.
  • Founded in 1979, SMDM promotes scientific and methodological rigor in health care decision research and its application to health policy and clinical care.
  • “We are pleased with the compounding interest in the Nociscan cost-effectiveness research,” said Ryan Bond, Chief Strategy Officer at Aclarion.
  • In July 2023, a Nociscan cost-effectiveness poster was presented at the American Society for Pain & Neuroscience (ASPN) annual meeting.

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

Retrieved on: 
Tuesday, October 17, 2023
Ophthalmology, ADHD, Plant, UCSF, University, Medicine, Arbutus Biopharma, Phase, Safety, Medical Center, CNS, University of California, San Francisco, Medical device, Polaris, Patient

(NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company's eight-week long ADHD Phase IIb clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers.

Key Points: 
  • (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company's eight-week long ADHD Phase IIb clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers.
  • Sixty-nine subjects enrolled in the study, 50 completed the study, and 11 are currently undergoing treatment.
  • The Phase IIb clinical study continues the Phase IIa clinical study of ABV-1505.
  • "We received a favorable response from the subjects participating in our ADHD Phase IIb study at all of our sites," said ABVC BioPharma Chief Executive Officer Uttam Patil, Ph.

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer

Retrieved on: 
Tuesday, October 10, 2023
Neoplasm, Partnership, Clinical Science (journal), Intelligence, Pembrolizumab, BID, CPI, UCSF, Trial of the century, SCNC, Safety, University, Survival, CTC, Disease, FDA, Therapy, RECIST, Webcast, Carcinoma, Associate, Prostate cancer, Progression-free survival, University of California, San Francisco, Patient, Pharmaceutical industry, Medicine

NEW HAVEN, Conn., Oct. 10, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced positive overall survival (OS) data from its Phase 2 trial of BXCL701, the Company's investigational oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in patients with small cell neuroendocrine prostate cancer (SCNC). As of a data cutoff of September 6, 2023, evaluable patients with SCNC (n=28) showed a median OS of 13.6 months (95% CI 10.9–NR), and a 12-month survival rate of 56.5%.

Key Points: 
  • “OS is the most meaningful measure by which the effectiveness of an oncology treatment is evaluated.
  • In 2023, there will be an estimated 288,3002 new patients with prostate cancer in the United States, with approximately 11,532 patients progressing to SCNC.
  • ET to discuss the data results from the Phase 2 trial of BXCL701.
  • Financial and other important information is routinely posted on and accessible through the Investors sections of its website at www.bioxceltherapeutics.com .